Lineage Cell Therapeutics Inc. (BT3)
XDUS 
Summary
BT3 Chart
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Discusses COR1 Cell Transplant Program and Manufacturing Strategy for Corneal Endothelial Disease Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell Therapeutics, Inc. (LCTX) Q1 2026 Earnings Call Transcript
Lineage Cell (LCTX) Reports Q1 Loss, Lags Revenue Estimates
Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.02 per share a year ago.
Lineage Cell Therapeutics Inc. (BT3) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Lineage Cell Therapeutics Inc. ever had a stock split?
Lineage Cell Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Brian Culley CEO | XDUS Exchange | US53566P1093 ISIN |
| US Country | 77 Employees | 15 Dec 2003 Last Dividend | 31 Oct 1997 Last Split | 6 Mar 1992 IPO Date |
Overview
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on the development of novel cell therapies to address unmet medical needs across the globe. Previously known as BioTime, Inc., the company underwent a rebranding to Lineage Cell Therapeutics, Inc. in August 2019. Since its incorporation in 1990, the organization has dedicated itself to pioneering treatments in areas ranging from retinal diseases and neurological disorders to oncology. Headquartered in Carlsbad, California, Lineage Cell Therapeutics, Inc. operates both in the United States and internationally, working towards innovative solutions for challenging medical conditions. Collaboration is also a key part of its strategy, as evidenced by its partnership with Immunomic Therapeutics, Inc. for the development of treatments for glioblastoma multiforme.
Products and Services
- OpRegen: An allogeneic retinal pigment epithelium cell replacement therapy currently in Phase 2a clinical trials. OpRegen is designed to treat dry age-related macular degeneration, a leading cause of blindness in older adults. This therapy aims to replace damaged cells in the retina, offering a potential innovative treatment for those affected by this condition.
- OPC1: In Phase 1/2a multicenter clinical trials, OPC1 is an allogeneic oligodendrocyte progenitor cell therapy aimed at treating cervical spinal cord injuries. By promoting the regeneration of myelin and facilitating neural function restoration, OPC1 represents a pioneering approach to addressing severe spinal cord injuries.
- VAC: This allogeneic cancer immunotherapy utilizes antigen-presenting dendritic cells and is currently in Phase I clinical trials targeting non-small cell lung cancer. VAC is part of Lineage's efforts to harness the body's immune system in the fight against cancer, offering a novel strategy for tackling this widespread disease.
- ANP1: Still in preclinical development, ANP1 is an allogeneic auditory neuron progenitor cell transplant aimed at treating debilitating hearing loss. This product represents Lineage's commitment to extending its cell therapy technologies to the realm of auditory disorders, with the potential to significantly impact quality of life for individuals with severe hearing impairments.
- PNC1: Another promising therapy in preclinical development, PNC1 involves an allogeneic photoreceptor cell transplant designed to treat vision loss attributable to photoreceptor dysfunction or damage. As part of its portfolio for retinal diseases, PNC1 underlines the company's dedication to addressing a broad spectrum of vision impairments through innovative cell therapy solutions.
